CRSP CRISPR Therapeutics AG - Common Shares
$56,87
Cena · Sie 19, 2026
Dane fundamentalne na dzień Sie 3, 2026
Zakres 52 tyg.
$44–$78
37% of range
Ocena Analityków
HOLD
29 analysts
Cena Docelowa
$88
+54% upside
P/E (TTM)
-8.8
ROE
-32.0%
Marża Zysku Netto
-16569.8%
O CRISPR Therapeutics AG - Common Shares Przegląd firmy z Wikipedii
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Czytaj więcej
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
CRSP Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$56.87
Kapitalizacja Rynkowa
$5.45B
P/E (TTM)
-8.8
EPS (TTM)
$-6.47
Przychody (TTM)
$4M
Stopa dywidendy
—
ROE
-32.0%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$44 – $78
CRSP Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-346M
2016-12-31
→
2025-12-31
Marże
-16569.8%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
CRSP
Mediana porównawcza
P/E (TTM)
-8.8
—
P/S (TTM)
1553.7
56.3
P/B
2.8
3.0
Price / FCF (Cena / FCF)
-15.8
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
CRSP
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-18933.7%
—
Net Profit Margin (Marża Zysku Netto)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
CRSP
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
13.3
6.7
Quick Ratio (Wskaźnik Szybkości)
13.2
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
CRSP
Mediana porównawcza
Revenue YoY (Przychody R/R)
-90.6%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
43.1%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
37.3%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
CRSP
Mediana porównawcza
CRSP Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
29 analityków
- Mocne kupno 6 20,7%
- Kup 11 37,9%
- Trzymaj 12 41,4%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
18 analityków · 2026-08-15
Mediana
$80.00
Teraz
$56.87
Niski
$44.00
Wysoki
$291.00
Średni cel
$80.00
+40,7%
Średnia cel
$87.56
+54,0%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.01%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-0.94 | $-1.22 | 0.28% |
| 31 marca 2026 | $-1.28 | $-1.25 | -0.03% |
| 31 grudnia 2025 | $-1.37 | $-1.18 | -0.19% |
| 30 września 2025 | $-1.17 | $-1.29 | 0.12% |
| 30 czerwca 2025 | $-1.29 | $-1.45 | 0.16% |
| 31 marca 2025 | $-1.58 | $-1.28 | -0.30% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 15
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Bilans 25
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Przepływy pieniężne 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efektywność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Bilans 25
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Przepływy pieniężne 11
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $4M | $37M | $371M | $1M | $915M |
| Marża Operacyjna % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Zysk netto | $-582M | $-366M | $-154M | $-650M | $378M |
| Rozwodniony EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Wskaźnik Szybkości | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-346M | $-145M | $-270M | $-533M | $457M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- Akcje CRISPR Therapeutics są absurdalnie tanie – oto dlaczego analitycy widzą 437% potencjału wzrostu
- Przywództwo Wzrostu Mega-Kapitalizacji czy Potencjał Wzrostu Małych Spółek? VUG vs VBK
- 1 Najwyższy analityk Wall Street uważa, że CRISPR Therapeutics może podwoić swoją wartość. Czy powinieneś kupować akcje bez opamiętania?
- Wykryto znaczący odpływ z ETF - ARKK, CRSP, TEM, HOOD
- Ten Biofarmaceutyczna Firma Ma Potencjał, Aby Zdefiniować Na Nowo Cały Obszar Terapeutyczny
- Cathie Wood Poluje na Okazje: 2 Akcje, Które Właśnie Kupowała
- Czy ten biotechnologiczny stock jest Twoją najlepszą szansą na zbudowanie pozycji milionera?
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 573 emitenci · $3.3B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 89 (0 vs poprzedni kw.) | 47 (-13 vs poprzedni kw.) | 148 (-24 vs poprzedni kw.) | 145 (+21 vs poprzedni kw.) | +5.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| ARK Investment Management LLC | $515 999 631 | 9 460 939 | 15,58% | Akcje |
| Orbis Allan Gray Ltd | $296 334 582 | 5 433 344 | 8,95% | Akcje |
| Capital World Investors | $259 039 094 | 4 749 525 | 7,82% | Akcje |
| STATE STREET CORP | $235 703 664 | 4 321 666 | 7,12% | Akcje |
| GSK plc | $175 652 997 | 3 220 627 | 5,30% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $117 453 717 | 2 153 015 | 3,55% | Akcje |
| SR One Capital Management, LP | $111 194 134 | 2 038 763 | 3,36% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $108 459 389 | 1 988 621 | 3,27% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $93 848 832 | 1 720 734 | 2,83% | Akcje |
| Amova Asset Management Americas, Inc. | $93 762 487 | 1 720 097 | 2,83% | Akcje |
| EcoR1 Capital, LLC | $75 771 113 | 1 389 276 | 2,29% | Akcje |
| Capital International Investors | $69 178 918 | 1 268 407 | 2,09% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $64 457 935 | 1 181 847 | 1,95% | Akcje |
| NEA Management Company, LLC | $57 734 408 | 1 058 570 | 1,74% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57 694 430 | 1 057 837 | 1,74% | Akcje |
| FMR LLC | $53 577 751 | 982 357 | 1,62% | Akcje |
| D. E. Shaw & Co., Inc. | $48 748 506 | 893 812 | 1,47% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35 380 807 | 648 713 | 1,07% | Akcje |
| UBS Group AG | $32 419 612 | 594 419 | 0,98% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $31 089 982 | 570 040 | 0,94% | Akcje |
| VANGUARD GROUP INC | $27 714 225 | 528 494 | 0,84% | Akcje |
| CITADEL ADVISORS LLC | $25 404 514 | 465 796 | 0,77% | Akcje |
| BANK OF AMERICA CORP /DE/ | $23 509 740 | 431 055 | 0,71% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 298 288 | 427 178 | 0,70% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $20 836 025 | 382 032 | 0,63% | Akcje |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20 833 789 | 381 991 | 0,63% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18 456 336 | 338 400 | 0,56% | Opcja sprzedaży |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17 763 678 | 325 700 | 0,54% | Opcja kupna |
| Logos Global Management LP | $16 362 000 | 300 000 | 0,49% | Akcje |
| CITADEL ADVISORS LLC | $15 822 054 | 290 100 | 0,48% | Opcja sprzedaży |
| Squarepoint Ops LLC | $15 641 472 | 286 789 | 0,47% | Akcje |
| NORGES BANK | $14 767 032 | 270 756 | 0,45% | Akcje |
| CITADEL ADVISORS LLC | $13 973 148 | 256 200 | 0,42% | Opcja kupna |
| GOLDMAN SACHS GROUP INC | $12 748 193 | 233 740 | 0,38% | Akcje |
| JANE STREET GROUP, LLC | $12 566 016 | 230 400 | 0,38% | Opcja kupna |
| PEAK6 LLC | $11 633 382 | 213 300 | 0,35% | Opcja sprzedaży |
| Swiss National Bank | $9 228 168 | 169 200 | 0,28% | Akcje |
| Susquehanna Portfolio Strategies, LLC | $8 945 978 | 164 026 | 0,27% | Akcje |
| TWO SIGMA ADVISERS, LP | $8 516 256 | 162 400 | 0,26% | Akcje |
| LPL Financial LLC | $8 376 280 | 153 581 | 0,25% | Akcje |
| Bank of New York Mellon Corp | $8 337 366 | 152 867 | 0,25% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $8 301 261 | 152 205 | 0,25% | Akcje |
| Versant Venture Management, LLC | $8 117 243 | 148 831 | 0,25% | Akcje |
| Pictet Asset Management Holding SA | $7 989 776 | 142 213 | 0,24% | Akcje |
| Life Cycle Investment Partners Ltd | $7 836 962 | 143 692 | 0,24% | Akcje |
| TD Asset Management Inc | $7 777 513 | 142 602 | 0,23% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $7 606 257 | 139 462 | 0,23% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $7 230 750 | 132 577 | 0,22% | Akcje |
| RHUMBLINE ADVISERS | $6 627 197 | 121 511 | 0,20% | Akcje |
| SFE Investment Counsel | $6 229 434 | 16 700 | 0,19% | Opcja sprzedaży |
| Private Advisor Group, LLC | $6 060 980 | 111 129 | 0,18% | Akcje |
| EverSource Wealth Advisors, LLC | $6 032 669 | 110 610 | 0,18% | Akcje |
| CONGRESS ASSET MANAGEMENT CO | $5 969 567 | 109 453 | 0,18% | Akcje |
| BlackRock, Inc. | $5 937 061 | 108 857 | 0,18% | Akcje |
| D. E. Shaw & Co., Inc. | $5 901 228 | 108 200 | 0,18% | Opcja kupna |
| Campbell & CO Investment Adviser LLC | $5 864 632 | 107 529 | 0,18% | Akcje |
| JANE STREET GROUP, LLC | $5 852 142 | 107 300 | 0,18% | Opcja sprzedaży |
| California Public Employees Retirement System | $5 599 567 | 102 669 | 0,17% | Akcje |
| CAPITAL INTERNATIONAL SARL | $5 521 521 | 101 238 | 0,17% | Akcje |
| Affinity Asset Advisors, LLC | $5 454 000 | 100 000 | 0,16% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $5 439 011 | 114 337 | 0,16% | Akcje |
| CLOUGH CAPITAL PARTNERS L P | $5 363 300 | 98 337 | 0,16% | Akcje |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5 172 465 | 94 838 | 0,16% | Akcje |
| Slow Capital, Inc. | $5 066 439 | 92 894 | 0,15% | Akcje |
| CAPITAL FUND MANAGEMENT S.A. | $4 867 258 | 89 242 | 0,15% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4 815 606 | 101 232 | 0,15% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $4 720 437 | 86 550 | 0,14% | Akcje |
| GROUP ONE TRADING LLC | $4 638 082 | 85 040 | 0,14% | Akcje |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4 575 742 | 83 897 | 0,14% | Akcje |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4 502 113 | 82 547 | 0,14% | Akcje |
| Concurrent Investment Advisors, LLC | $4 497 728 | 82 467 | 0,14% | Akcje |
| WELLS FARGO & COMPANY/MN | $4 309 151 | 79 009 | 0,13% | Akcje |
| Fisher Asset Management, LLC | $4 251 957 | 77 960 | 0,13% | Akcje |
| Trexquant Investment LP | $4 225 268 | 77 471 | 0,13% | Akcje |
| COMMONWEALTH EQUITY SERVICES, LLC | $4 194 122 | 76 900 | 0,13% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $4 055 652 | 73 847 | 0,12% | Akcje |
| Man Group plc | $3 992 001 | 73 194 | 0,12% | Akcje |
| PEAK6 LLC | $3 834 162 | 70 300 | 0,12% | Opcja kupna |
| ENVESTNET ASSET MANAGEMENT INC | $3 822 196 | 70 081 | 0,12% | Akcje |
| ALGERT GLOBAL LLC | $3 593 095 | 65 880 | 0,11% | Akcje |
| Walleye Trading LLC | $3 528 738 | 64 700 | 0,11% | Opcja sprzedaży |
| MILLENNIUM MANAGEMENT LLC | $3 146 958 | 57 700 | 0,10% | Opcja kupna |
| CAPITAL INTERNATIONAL LTD /CA/ | $3 057 840 | 56 066 | 0,09% | Akcje |
| NOMURA HOLDINGS INC | $3 055 713 | 56 027 | 0,09% | Akcje |
| Rafferty Asset Management, LLC | $3 045 132 | 55 833 | 0,09% | Akcje |
| Green Alpha Advisors, LLC | $3 043 550 | 55 804 | 0,09% | Akcje |
| Walleye Trading LLC | $3 005 154 | 55 100 | 0,09% | Opcja kupna |
| Caption Management, LLC | $2 999 700 | 55 000 | 0,09% | Opcja kupna |
| MetLife Investment Management, LLC | $2 958 413 | 54 243 | 0,09% | Akcje |
| BENJAMIN EDWARDS INC | $2 956 845 | 54 216 | 0,09% | Akcje |
| Quantinno Capital Management LP | $2 869 349 | 52 610 | 0,09% | Akcje |
| Cetera Investment Advisers | $2 856 133 | 52 368 | 0,09% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $2 788 521 | 51 128 | 0,08% | Akcje |
| CITIGROUP INC | $2 781 540 | 51 000 | 0,08% | Opcja kupna |
| CITIGROUP INC | $2 781 540 | 51 000 | 0,08% | Opcja sprzedaży |
| WOLVERINE ASSET MANAGEMENT LLC | $2 727 000 | 50 000 | 0,08% | Opcja sprzedaży |
| OSAIC HOLDINGS, INC. | $2 693 150 | 49 381 | 0,08% | Akcje |
| Privium Fund Management B.V. | $2 452 882 | 44 974 | 0,07% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $2 394 306 | 43 900 | 0,07% | Akcje |
| TUDOR INVESTMENT CORP ET AL | $2 318 604 | 42 512 | 0,07% | Akcje |
Insiderzy spółki 32 insiderów · 12 dyrektorzy generalni · 16 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 marca 2026 M | 255 501 | 0 | 9 | $-10 756 932 |
| Brendan Smith | Chief Financial Officer | 18 lutego 2023 M | 5 072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 marca 2021 M | 1 891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 marca 2025 M | 10 544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 sierpnia 2022 A | 26 797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 29 maja 2026 A | 19 357 | 1 | 2 | $-312 892 |
| James R. Kasinger | General Counsel and Secretary | 29 maja 2026 A | 94 308 | 0 | 5 | $-645 902 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 października 2023 A | 4 411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 grudnia 2021 M | 52 364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 stycznia 2018 M | 25 204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 czerwca 2017 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 października 2016 C | 505 617 | 0 | 0 | $0 |
| Christian Rommel | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Douglas A Treco | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Briggs Morrison | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Katherine A High | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Ali Behbahani | Dyrektor | 5 czerwca 2026 A | 14 | 0 | 0 | $0 |
| John Greene | Dyrektor | 5 czerwca 2026 A | 7 000 | 0 | 0 | $0 |
| Simeon George | Dyrektor | 5 czerwca 2026 A | 1 730 179 | 0 | 0 | $0 |
| Maria Fardis | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | Dyrektor | 5 czerwca 2026 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Dyrektor | 9 czerwca 2022 A | 148 831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Dyrektor | 19 listopada 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Dyrektor | 18 grudnia 2018 S | 1 171 268 | 0 | 0 | $0 |
| Thomas Woiwode | Dyrektor | 15 czerwca 2018 A | 640 014 | 0 | 0 | $0 |
| Anthony N Coles | Dyrektor | 31 maja 2017 A | 70 000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Posiadacz 10% | 4 grudnia 2017 S | 3 722 534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Posiadacz 10% | 24 października 2016 C | 744 380 | 0 | 0 | $0 |
| GSK plc | Posiadacz 10% | 24 października 2016 C | 3 220 627 | 0 | 0 | $0 |
| Raju Prasad | — | 7 sierpnia 2026 G | 14 815 | 0 | 10 | $-5 100 841 |
| Rodger Novak | — | 30 czerwca 2021 S | 573 007 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 zgłoszenia | 16 lutego 2021 | — | Pierwotne zgłoszenie | — | SEC |
| GlaxoSmithKline plc ×5 zgłoszenia | 10 lipca 2020 | — | Pierwotne zgłoszenie | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 zgłoszenia | 4 lutego 2020 | — | Pierwotne zgłoszenie | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 zgłoszenia | 7 czerwca 2019 | — | Pierwotne zgłoszenie | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 zgłoszenia | 8 lutego 2018 | — | Pierwotne zgłoszenie | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 zgłoszenia | 16 stycznia 2018 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 32 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| GNOM · Global X Funds | 3,85% | 38 191 NS | 31 maja 2026 | N-PORT |
| IDNA · iShares Trust | 1,63% | 62 247 SH | 8 sierpnia 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,98% | 97 235 NS | 30 kwietnia 2026 | N-PORT |
| IBB · iShares Trust | 0,36% | 658 537 SH | 8 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 5 248 SH | 8 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70 696 SH | 8 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | 0,27% | 752 223 SH | 8 sierpnia 2026 | Dziennie |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,21% | 104 016 NS | 31 maja 2026 | N-PORT |
| ISCV · iShares Trust | 0,15% | 20 568 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,15% | 2 353 025 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536 446 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,15% | 39 589 NS | 30 kwietnia 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,10% | 6 636 SH | 8 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | 0,07% | 4 136 SH | 8 sierpnia 2026 | Dziennie |
| SMLF · iShares Trust | 0,07% | 57 970 SH | 8 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1 106 455 SH | 8 sierpnia 2026 | Dziennie |
| ESML · iShares Trust | 0,06% | 33 283 SH | 8 sierpnia 2026 | Dziennie |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,06% | 108 NS | 31 maja 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 5 486 SH | 8 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13 170 SH | 8 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,04% | 109 974 SH | 8 sierpnia 2026 | Dziennie |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1 736 SH | 8 sierpnia 2026 | Dziennie |
| XT · iShares Trust | 0,03% | 21 837 SH | 8 sierpnia 2026 | Dziennie |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,03% | 3 509 NS | 31 maja 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7 774 SH | 8 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20 627 SH | 8 sierpnia 2026 | Dziennie |
| IYY · iShares Trust | 0,01% | 4 231 SH | 8 sierpnia 2026 | Dziennie |
| ITOT · iShares Trust | 0,01% | 128 511 SH | 8 sierpnia 2026 | Dziennie |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,01% | 15 609 NS | 31 maja 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 25 457 SH | 8 sierpnia 2026 | Dziennie |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 289 NS | 31 maja 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75 392 SH | 8 sierpnia 2026 | Dziennie |